NRC Health (NASDAQ: NRC) is a Healthcare company (Medical - Healthcare Information Services) with a market capitalization of $549M. The Maz Rating grades it against the other companies in its sector.
NRC Health's current Maz Rating and its five factor grades are for members: log in to see them.
At $25.89, NRC Health trades at 85.2x trailing earnings and 3.8x sales, with an EV/EBITDA of 26.5. Over the last twelve months it generated about $144M of revenue and $6M of net income. It runs a gross margin of 47.9%, an operating margin of 11.1% and a net margin of 4.5%. It shows return on equity of 103.4%, return on invested capital of 9.5% and a free cash flow yield of 3.4%. On the balance sheet: a debt-to-equity ratio of -11.28 and a current ratio of 0.64. Over the past 52 weeks the share price ranged from $11.73 to $27.60, with a beta of 0.38.
NRC Health pays a dividend yielding 2.48%, with 209% of earnings paid out. Its Maz Dividend Score is 1.17 out of 5, ranked against the other dividend payers in its sector (Safety 1.03, Growth 3.63, Yield 3.83, Consistency 1.24).
1 Wall Street analyst rating covers the stock: 1 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, NRC Health (NRC) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 21.2% / 30% · (Cash+Inv) / Mkt Cap (36m) 0.75% / 30% · Interest income / Revenue 0.07% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 21.2% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 0.75% / 33% · Receivables / Mkt Cap (36m) 3.16% / 49% · Interest income / Revenue 0.07% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 21.2% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 0.75% / 33.33% · Receivables / Mkt Cap (24m) 3.16% / 33.33% · Interest income / Revenue 0.07% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 64.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 2.50% / 33.33% · Receivables / Avg Assets (4Q) 9.53% / 33.33% · Interest income / Revenue 0.07% / 5% | Fail |
| FTSE | Debt / Total Assets 73.9% / 33.33% · (Cash+ST Inv) / Total Assets 2.60% / 33.33% · (Cash+Recv) / Total Assets 13.6% / 33.33% · Interest income / Revenue 0.07% / 5% | Fail |
It depends on the standard you follow. As of September 2026, NRC Health (NRC) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. NRC Health is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.07% of each dividend: NRC Health's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.